| Previous Close | Open | Close* |
|---|---|---|
| 0.09 | 0.086 | 0.086 |
| Market Cap | Dividend Yield (Annualized) |
|---|---|
| AUD 16.684M | 0.00% |
| Day Range |
|---|
| 0.086L 0.086 H |
| 52 WEEK HIGH LOW |
|---|
| 0.08L 0.18 H |
| Last Trade | 0.086 |
|---|---|
| Change% | -4.4444 |
| 52 W H/L | 0.180/0.080 |
| EBITDA | -4.423M |
| NPAT After Abnormal Items | -3.644M |
| Equity | 21.848M |
| ROE% | -16.68% |
| Total Liabilities | 2.636M |
| Total Revenue | 1.983M |
| Cash and Cash Equivalents | 14.609M |
| Share price | 0.086 |
|---|---|
| Market Cap | 16.684M |
| Price/Gross Cash Flow | -11.03 |
| Dividend Yield Excluding Special | 0.00% |
| Ending Shares | 193.854M |
| 52-Week Range | 0.180-0.080 |
| Gross DPS (AUD) | 0 |
| Gross Dividend Yield (Annualized) | 0.00% |
| Earnings Yield | 0.000 |
| Net Tangible Asset (NTA) | 0.07 |
| P/E ratio | 0.000 |
| Sector P/E | -- |
| EPS | -2.50 |
| EV/EBITDA | -- |
| Net Profit Margin (%) | -- |
| Gross Cash Flows Per Share | -0.02 |
| Net Gearing | -57.25% |
| Sales Per Share | 0.00 |
| Book Value Per Share | 0.11 |
Amplia Therapeutics Limited is based in Melbourne, Australia. It is engaged with the development of FAK (Focal Adhesion Kinase) for the treatment of diseases like cancer and fibrosis. FAK is positioning itself as a significant pick in the cancer immunology and Amplia. Some of the company’s drug candidate include- AMP945 & AMP886.
Level 21, 90 Collins Street, MELBOURNE, VIC, AUSTRALIA, 3000
| Ex-Date | Net Dividend | Frank Flag | Period End Date | Type | Payable |
|---|
| Event Type | Event Date | Event Year |
|---|---|---|
| Report (Interim) | 2023-11-17 | 2023 |
| Report (Annual) | 2023-05-29 | 2023 |
| Report (Prelim) | 2023-05-29 | 2023 |